Literature DB >> 7492007

Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome?

W L Biffl1, F A Moore, E E Moore, J B Haenel, R C McIntyre, J M Burch.   

Abstract

BACKGROUND: Late acute respiratory distress syndrome (ARDS), characterized by progressive pulmonary interstitial fibroproliferation, is associated with mortality > 80%. Although previous large prospective trials failed to show a benefit of steroids in early ARDS, recent small reports describe improved survival in patients with late ARDS. Recognizing the pathogenetic differences between early and late ARDS, we employed steroid therapy in patients with refractory late ARDS. PATIENTS AND METHODS: Over a 5-year period, we treated 6 patients who were dying of isolated refractory ARDS with methylprednisolone sodium succinate (1 to 2 mg/kg every 6 hours). Ventilatory parameters and lung injury scores were serially recorded, and steroids were weaned based on clinical response.
RESULTS: Steroids were instituted after 16 days of advanced mechanical ventilatory support. By day 7 of steroid therapy, there was clinically significant improvement in PaO2/FiO2 ratios (84 to 172) and lung injury scores (3.6 to 2.9); 5 patients (83%) survived.
CONCLUSIONS: Steroid therapy appears to be effective in patients with refractory late ARDS. Prospective trials are needed to define the indications, timing of intervention, dose and duration, and precautions of steroid therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492007     DOI: 10.1016/s0002-9610(99)80022-1

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  14 in total

Review 1.  The pulmonary physician in critical care - part 9: non-ventilatory strategies in ARDS.

Authors:  J Cranshaw; M J D Griffiths; T W Evans
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

2.  Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis.

Authors:  Avinandan Saha; Preyas J Vaidya; Vinod B Chavhan; Amolkumar Achlerkar; Jörg D Leuppi; Prashant N Chhajed
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

3.  The potential role of BAX and BCL-2 expression in diffuse alveolar damage.

Authors:  D Guinee; E Brambilla; M Fleming; T Hayashi; M Rahn; M Koss; V Ferrans; W Travis
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

4.  Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia.

Authors:  Wei Zhou; Yisi Liu; Dongdong Tian; Cheng Wang; Sa Wang; Jing Cheng; Ming Hu; Minghao Fang; Yue Gao
Journal:  Signal Transduct Target Ther       Date:  2020-02-21

Review 5.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

Review 6.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

7.  Steroids in late ARDS?

Authors:  Non Wajanaponsan; Michael C Reade; Eric B Milbrandt
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

8.  Steroid-induced osteonecrosis in severe acute respiratory syndrome: a retrospective analysis of biochemical markers of bone metabolism and corticosteroid therapy.

Authors:  Michael H M Chan; Paul K S Chan; James F Griffith; Iris H S Chan; Lydia C W Lit; C K Wong; Gregory E Antonio; Ester Y M Liu; David S C Hui; Michael W M Suen; Anil T Ahuja; Joseph J Y Sung; Christopher W K Lam
Journal:  Pathology       Date:  2006-06       Impact factor: 5.306

9.  Succinate Activation of SUCNR1 Predisposes Severely Injured Patients to Neutrophil-Mediated ARDS.

Authors:  Geoffrey R Nunns; Navin Vigneshwar; Marguerite R Kelher; Gregory R Stettler; Lajos Gera; Julie A Reisz; Angelo D'Alessandro; Joshua Ryon; Kirk C Hansen; Fabia Gamboni; Ernest E Moore; Erik D Peltz; Mitchell J Cohen; Kenneth L Jones; Angela Sauaia; Xiayuan Liang; Anirban Banerjee; Arsen Ghasabyan; James G Chandler; Sophia Rodawig; Carter Jones; Andrew Eitel; Patrick Hom; Christopher C Silliman
Journal:  Ann Surg       Date:  2020-11-18       Impact factor: 12.969

Review 10.  Rationale for Prolonged Glucocorticoid Use in Pediatric ARDS: What the Adults Can Teach Us.

Authors:  Andreas Schwingshackl; Gianfranco Umberto Meduri
Journal:  Front Pediatr       Date:  2016-06-14       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.